Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

KC Lee, PS Wu, HC Lin - Clinical and molecular hepatology, 2022 - pmc.ncbi.nlm.nih.gov
The initial presentation of non-alcoholic steatohepatitis (NASH) is hepatic steatosis. The
dysfunction of lipid metabolism within hepatocytes caused by genetic factors, diet, and …

Update on NAFLD genetics: from new variants to the clinic

E Trépo, L Valenti - Journal of hepatology, 2020 - Elsevier
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver diseases in high-
income countries and the burden of NAFLD is increasing at an alarming rate. The risk of …

Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease

Y Chen, X Du, A Kuppa, MF Feitosa, LF Bielak… - Nature …, 2023 - nature.com
Nonalcoholic fatty liver disease (NAFLD) is common and partially heritable and has no
effective treatments. We carried out a genome-wide association study (GWAS) meta …

[HTML][HTML] Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆

QM Anstee, R Darlay, S Cockell, M Meroni… - Journal of …, 2020 - Elsevier
Background & Aims Genetic factors associated with non-alcoholic fatty liver disease
(NAFLD) remain incompletely understood. To date, most genome-wide association studies …

RNA N6‐methyladenosine methyltransferase‐like 3 promotes liver cancer progression through YTHDF2‐dependent posttranscriptional silencing of SOCS2

M Chen, L Wei, CT Law, FHC Tsang, J Shen… - Hepatology, 2018 - journals.lww.com
Epigenetic alterations have contributed greatly to human carcinogenesis. Conventional
epigenetic studies have predominantly focused on DNA methylation, histone modifications …